

24 August 2010

## Proposal relating to the funding of travoprost

PHARMAC is seeking feedback on a proposal relating to a provisional agreement with Pharmaco (NZ) Ltd for the glaucoma treatment, travoprost (Travatan).

This proposal would mean that reference pricing would not occur as previously notified on 12 March 2010<sup>1</sup> but would result in travoprost (Travatan) eye drops remaining fully subsidised.

### Feedback sought

PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by **Monday, 6 September 2010** to:

Sue Anne Yee  
 Therapeutic Group Manager  
 PHARMAC  
 PO Box 10 254  
 Wellington 6143

Email: [sueanne.yee@pharmac.govt.nz](mailto:sueanne.yee@pharmac.govt.nz)

Fax: 04 460 4995

All feedback received before the closing date will be considered by PHARMAC's Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal.

### Details of the proposal

Travoprost would be fully funded in Section B of the Pharmaceutical Schedule at the following price and subsidy (ex-manufacturer, exclusive of GST) from 1 October 2010:

Chemical	Presentation	Brand	Pack size	Current subsidy and price	Proposed subsidy and price
Travoprost	Eye drops 0.004%	Travatan	2.5mL OP	9.75 (19.50)	19.50

Travatan would be protected from subsidy reduction or delisting until 30 June 2012. A confidential rebate would also apply to Travatan.

### Background

In April 2010, the subsidy for travoprost was reference priced to the subsidy of latanoprost. This was subject of a notification letter dated 12 March 2010<sup>1</sup>. To allow sufficient time for patients to return to their ophthalmologists for a review of their medication, a six month transition period was provided. During this transition period from 1 April 2010 until 30

September 2010, additional subsidy by endorsement is available for patients who were prescribed travoprost prior to 1 April 2010.

Subsequent to the notification of reference pricing, PHARMAC and Pharmaco (NZ) Ltd have entered into a provisional agreement which would enable travoprost to continue to be fully subsidised at its current list price of \$19.50, until at least 30 June 2012.

1. <http://www.pharmac.govt.nz/2010/03/12>